Trials / Withdrawn
WithdrawnNCT02521233
Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- EMS · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Candesartan + Chlorthalidone (8mg+12,5mg) | |
| DRUG | Candesartan + Chlorthalidone (8 mg + 25 mg) | |
| DRUG | losartan+hydrochlorothiazide |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2017-05-01
- Completion
- 2017-08-01
- First posted
- 2015-08-13
- Last updated
- 2017-01-19
Source: ClinicalTrials.gov record NCT02521233. Inclusion in this directory is not an endorsement.